FDA Brief

Warning letters Food

FDA warning letter to

Deggeh Foods, Inc.

High riskIssued Jul 29, 2022Posted Aug 16, 2022Office of Human and Animal Food Operations East – Division 1

FDA says Deggeh Foods sold supplement capsules and Moringa tea as unapproved drugs and violated manufacturing rules.

What happened

FDA inspected Deggeh Foods' Bronx facility from November 29, 2021 to January 10, 2022, and reviewed the company website in June 2022 and its Facebook page. FDA found disease-treatment claims for Actibest, Best Hemorrhoids, StomachAID, and Moringa Tea Bags, making them unapproved new drugs, plus current good manufacturing practice (CGMP) violations for dietary supplements. FDA also found many dietary supplement labeling violations.

What FDA found

  1. The website, Facebook page, and labels claimed the capsules and tea could treat or prevent diseases such as cancer, diabetes, and high blood pressure, so FDA considers them unapproved new drugs.

    section 201(g)(1)(B) and 505(a) of the Act [21 U.S.C. 321(g)(1)(B), 355(a)]
  2. Actibest, StomachAID, and Moringa Tea Bags lacked adequate directions for safe use by a layperson, so FDA considers them misbranded drugs.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  3. The company did not establish required specifications for incoming products and for packaging and labeling of finished supplements.

    21 CFR 111.70(f), (g)
  4. The company did not establish or follow written quality control procedures, including material review and disposition decisions.

    21 CFR 111.103
  5. The company did not have written packaging and labeling procedures and did not use a lot number or other unique identifier to trace manufacturing history.

    21 CFR 111.403; 21 CFR 111.410(d)
  6. The company lacked written cleaning and pest-control procedures and packaged peanut powder in the same area as other products without cleaning or monitoring documents to prevent cross-contamination.

    21 CFR 111.16; 21 CFR 111.25(c)

What FDA wants

FDA tells Deggeh Foods to correct the drug claims and dietary supplement CGMP and labeling violations and to provide evidence of corrective actions; the provided letter does not state a response deadline.

Who should pay attention

  • retailers and online sellers of Deggeh products
  • dietary supplement brands using contract packagers
  • quality teams managing allergen cross-contact

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk